Recursion officer files notice to sell 22K shares

RECURSION PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) is the issuer for which officer Najat Khan has filed a Rule 144 notice to potentially sell shares of common stock. The notice covers 22,408 shares, with an indicated aggregate market value of $78,822.38, to be sold through Merrill Lynch on NASDAQ.

The shares include blocks of 18,422 and 6,477 common shares that were acquired as equity compensation on August 15, 2026. The filing does not itself report that any sale has occurred; it gives advance notice of a possible sale under Rule 144.

Key Figures

Shares covered by Rule 144 notice: 22,408 shares Aggregate market value: $78,822.38 Equity compensation block 1: 18,422 shares +2 more

5 metrics

Shares covered by Rule 144 notice 22,408 shares Common stock of Recursion Pharmaceuticals, Inc. covered for potential sale

Aggregate market value $78,822.38 Value associated with 22,408 RXRX shares in the Rule 144 notice

Equity compensation block 1 18,422 shares Common shares acquired as equity compensation on August 15, 2026

Equity compensation block 2 6,477 shares Common shares acquired as equity compensation on August 15, 2026

Acquisition date of compensated shares August 15, 2026 Date both equity compensation share blocks were acquired

Key Terms

Rule 144, Equity Compensation, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Equity Compensation financial

"Common | 08/15/2026 | Equity Compensation | Recursion Pharmaceuticals"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

aggregate market value financial

"Common | Merrill Lynch ... | 22408 | 78822.38 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for RXRX by Najat Khan disclose?

It discloses that officer Najat Khan has filed a Rule 144 notice covering the potential sale of 22,408 shares of Recursion Pharmaceuticals, Inc. common stock, with an indicated aggregate market value of $78,822.38, to be sold through Merrill Lynch on NASDAQ.

How many RXRX shares are covered by this Form 144 notice?

The notice covers 22,408 shares of Recursion Pharmaceuticals, Inc. common stock. These shares reflect potential sales reported under Rule 144 and do not by themselves confirm that any trades have occurred.

What is the reported market value of the RXRX shares in this Form 144?

The filing lists an aggregate market value of $78,822.38 for the 22,408 RXRX common shares covered by the Rule 144 notice. This figure is based on the price information provided at the time of the notice.

How were the RXRX shares in the Form 144 obtained by Najat Khan?

The shares were obtained as equity compensation. The filing identifies two blocks of common stock, 18,422 shares and 6,477 shares, each acquired on August 15, 2026 as equity compensation from Recursion Pharmaceuticals.

Does the Form 144 for RXRX mean the shares have already been sold?

No. A Form 144 is an advance notice of a proposed sale under Rule 144. The filing indicates the intention and maximum amount that may be sold but does not confirm that any of the 22,408 shares have actually been sold.

On which market may the RXRX shares in this Form 144 be sold?

The filing states that the 22,408 RXRX common shares covered by the notice may be sold on NASDAQ through Merrill Lynch.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 02:30 PM EDT Accepted by SEC EDGAR 09/08/2026 - 02:28 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002020969
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Recursion Pharmaceuticals, Inc.
SEC File Number	001-40323
Address of Issuer	41 S Rio Grande Street Salt Lake City UTAH 84101
Phone	385-269-0203
Name of Person for Whose Account the Securities are To Be Sold	Najat Khan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 301 Tresser Blvd. Stamford CT 06901	22408	78822.38	514895802	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2026	Equity Compensation	Recursion Pharmaceuticals			18422	08/15/2026	Equity Compensation
Common	08/15/2026	Equity Compensation	Recursion Pharmaceuticals			6477	08/15/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Najat Khan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)